If enacted, AB 1366 would notably adjust the reimbursement framework, where presently, pharmacist services receive reimbursement at 85% of the physician service fee schedule. With the proposed alignment, it balances the reimbursement incentives for advanced practice pharmacists, thereby encouraging wider provider participation in health service offerings. Additionally, the bill includes mandating that health care service plans and disability insurers reimburse eligible advanced practice pharmacists for services rendered, which promotes the integration of pharmacy services in health care delivery.
Summary
Assembly Bill 1366, introduced by Assembly Member Flora, aims to amend existing laws pertaining to the reimbursement of pharmacist services in California. Specifically, it seeks to establish that the rates of reimbursement for advanced practice pharmacists will be set at the same level as those for licensed physicians. This amendment is significant as it reflects an evolving recognition of the role of pharmacists in providing essential health services, especially within the Medi-Cal program, which serves low-income individuals. The bill anticipates federal approval to align the Medi-Cal reimbursements with these updated provisions, focusing on enhancing the value and accessibility of pharmacist-provided care.
Sentiment
The general sentiment surrounding AB 1366 seems to be supportive among health care advocates and professionals who view the bill as a step toward recognizing the indispensable contributions of pharmacists in patient care. However, there are concerns regarding potential regulatory implications and the financial impact on state programs. Opponents may argue that while the intent to enhance pharmacist capabilities is valid, the fiscal responsibilities without corresponding budget adjustments could strain existing health care frameworks, thereby complicating care delivery.
Contention
Noteworthy points of contention include the potential challenges in implementing these changes without the requisite federal approvals, which are essential for the effective function of the Medi-Cal program. Furthermore, the bill introduces provisions that classify willful violations of the reimbursement mandates as crimes, thus imposing a state-mandated local program. This aspect raises discussions around regulatory overreach and its implications for the health care service landscape, particularly how compliance will be monitored and enforced.
Requesting The Director Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.
Requesting The Department Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.
Requesting The Director Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.
Requesting The Department Of Commerce And Consumer Affairs To Establish And Convene A Pharmacy Reimbursement Working Group To Explore And Propose Legislation For The 2026 Legislative Session.